Capricor Therapeutics (CAPR) Cash & Current Investments (2010 - 2026)

Capricor Therapeutics' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $278.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 92.44% year-over-year to $278.6 million; the TTM figure through Mar 2026 stood at $278.6 million (up 92.44% YoY), while the FY2025 annual figure was $318.1 million, up 109.96% from the prior year.
• Cash & Current Investments was $278.6 million for Q1 2026 at Capricor Therapeutics, down from $318.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $318.1 million in Q4 2025 to a low of $28.5 million in Q3 2023.
• Historically, Cash & Current Investments has averaged $95.2 million across 5 years, with a median of $51.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments tumbled 38.81% in 2023, then surged 316.81% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $41.4 million in 2022, then slipped by 4.67% to $39.5 million in 2023, then soared by 283.7% to $151.5 million in 2024, then jumped by 109.96% to $318.1 million in 2025, then slipped by 12.42% to $278.6 million in 2026.
• The last three Cash & Current Investments figures came in at $278.6 million (Q1 2026), $318.1 million (Q4 2025), and $98.6 million (Q3 2025), per Business Quant data.